Evidence map›Paper›PMID 42881296›Full record

ReviewThe AAPS journal2026

The Patient-Centric Formulation Compass: A Proposed Bottom-Up Framework to Translate Population Insights into Product Design.

Domagoj Segregur, Pascal Somville, Jérôme Mantanus, Talia Flanagan

Abstract readReview
PubMed Publisher
In one paragraph

Review in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Domagoj SegregurCMC Development Sciences, UCB Pharma, Campus UCB, T3, Avenue de L'Industrie, Braine-L'Alleud, 1420, Belgium. Domagoj.segregur@ucb.com.ORCID http://orcid.org/0000-0002-7919-5319
Pascal SomvilleCMC Development Sciences, UCB Pharma, Campus UCB, T3, Avenue de L'Industrie, Braine-L'Alleud, 1420, Belgium.ORCID http://orcid.org/0009-0008-7591-0814
Jérôme MantanusCMC Development Sciences, UCB Pharma, Campus UCB, T3, Avenue de L'Industrie, Braine-L'Alleud, 1420, Belgium.ORCID http://orcid.org/0009-0001-6156-063X
Talia FlanaganCMC Development Sciences, UCB Pharma, Campus UCB, T3, Avenue de L'Industrie, Braine-L'Alleud, 1420, Belgium.ORCID http://orcid.org/0009-0007-8136-5616

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient-centricity is increasingly recognized as an important objective in pharmaceutical development. However, despite growing emphasis on incorporating patient perspectives into medicine design, limited guidance exists on how patient-centric insights can be systematically translated into administration route and formulation selection during early development. This white paper discusses the challenge associated with integrating patient-centric considerations into formulation-related decision-making and presents the authors' perspective on how these challenges may be addressed through a structured framework. To support this objective, the Patient-Centric Formulation Compass (PCFC) is proposed as a framework that links patient and disease understanding with administration route selection, formulation assessment, developability considerations, and downstream development planning. The framework consists of four sequential stages: 1) assessment of the target population and disease, 2) identification of suitable administration routes and formulation options, 3) evaluation of drug candidate compatibility and optimization opportunities, and 4) consolidation of the resulting knowledge into a transparent development summary. Rather than introducing new patient-centric principles, PCFC aims to operationalize and connect existing concepts within a structured and repeatable decision-support approach that may facilitate multidisciplinary discussion and formulation strategy development. The framework is proposed as a reference model that organizations may adapt to their own context and expertise. Its utility and impact should be evaluated through broader application across diverse development programs and therapeutic areas.

Indexed as

Drug DesignDrug DevelopmentPatient-Centered CareChemistry, PharmaceuticalDrug Administration RoutesHumansBiopharmaceuticsDrug developmentFormulation designPatient-centric

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.